Scientific publications

CT screening for lung cancer: comparison of three baseline screening protocols

Henschke CI (1,2,3), Yip R (4), Ma T (4,5), Aguayo SM (6), Zulueta J (7), Yankelevitz DF (4); Writing Committee for the I-ELCAP Investigators.

(1) Icahn School of Medicine at Mount Sinai, New York, NY, USA. Claudia.
(2) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA. Claudia.
(3) Department of Radiology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY, 10029, USA. Claudia.
(4) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
(5) Department of Diagnostic Ultrasound, Tong Ren Hospital, Capital Medical University, Beijing, 100730, China.
(6) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA.
(7) Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Navarra, Spain.

Magazine: European Radiology

Date: Dec 3, 2018

Pneumology

PURPOSE:

Clinical management decisions arising from the baseline round for lung cancer screening are the most challenging, as findings have accumulated over a lifetime and may be of no clinical concern. To minimize unnecessary harms and costs of workup prior to the first, annual repeat screening, workup should be limited to participants with the highest suspicion of lung cancer while still aiming to identify small, early lung cancers.

METHODS:

We compared recommendations for immediate, delayed (by 3 or 6 months) workup to assess growth at a malignant rate, and the resulting overall and potential biopsies of three baseline screening protocols: I-ELCAP, the two scenarios of ACR-LungRADS, and the European Consortium. For each protocol, the efficiency ratio (ER) of each recommendation was calculated by dividing the number of participants recommended for that workup by the number of resulting lung cancer diagnoses. The ER for potential biopsies was calculated, assuming that biopsies were performed on all participants recommended for immediate workup as well as those diagnosed with lung cancer after delayed workup.

RESULTS:

For I-ELCAP, ACR-LungRADS Scenario 1, ACR-LungRADS Scenario 2, and the European consortium, the overall ER was 13.9, 18.3, 18.3, and 31.9, respectively, and for potential biopsies, it was 2.2, 8.1, 3.2, and 4.4, respectively. ER for immediate workup was 2.9, 8.6, 3.9, and 5.6, respectively, and for delayed workup was 36.1, 160.3, 57.8, and 111.9, respectively.

CONCLUSIONS:

I-ELCAP recommendations had the lowest ER values for overall, immediate, and delayed workup, and for potential biopsies.

KEY POINTS:

• Small differences in protocol thresholds can lead to many unnecessary diagnostic workups. • I-ELCAP recommendations were the most efficient for immediate and overall workup, and potential biopsies. • Definition of a "positive result" and recommendations for further workup in the baseline round needs to be continually reevaluated and updated.

CITATION  Eur Radiol. 2018 Dec 3. doi: 10.1007/s00330-018-5857-5.

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra